Literature DB >> 34912100

Innovative therapies to tackle platinum-resistant ovarian cancer.

Amanda B Keener.   

Abstract

Entities:  

Keywords:  Cancer; Health care; Therapeutics

Year:  2021        PMID： 34912100     DOI： 10.1038/d41586-021-03718-6

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  11 in total

1.  Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.

Authors:  Stephanie Lheureux; Mihaela C Cristea; Jeffrey P Bruce; Swati Garg; Michael Cabanero; Gina Mantia-Smaldone; Alexander B Olawaiye; Susan L Ellard; Johanne I Weberpals; Andrea E Wahner Hendrickson; Gini F Fleming; Stephen Welch; Neesha C Dhani; Tracy Stockley; Prisni Rath; Katherine Karakasis; Gemma N Jones; Suzanne Jenkins; Jaime Rodriguez-Canales; Michael Tracy; Qian Tan; Valerie Bowering; Smitha Udagani; Lisa Wang; Charles A Kunos; Eric Chen; Trevor J Pugh; Amit M Oza
Journal:  Lancet       Date:  2021-01-23       Impact factor: 79.321

2.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Authors:  Eric Pujade-Lauraine; Felix Hilpert; Béatrice Weber; Alexander Reuss; Andres Poveda; Gunnar Kristensen; Roberto Sorio; Ignace Vergote; Petronella Witteveen; Aristotelis Bamias; Deolinda Pereira; Pauline Wimberger; Ana Oaknin; Mansoor Raza Mirza; Philippe Follana; David Bollag; Isabelle Ray-Coquard
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

3.  Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.

Authors:  Panagiotis A Konstantinopoulos; Su-Chun Cheng; Andrea E Wahner Hendrickson; Richard T Penson; Susan T Schumer; L Austin Doyle; Elizabeth K Lee; Elise C Kohn; Linda R Duska; Marta A Crispens; Alexander B Olawaiye; Ira S Winer; Lisa M Barroilhet; Siqing Fu; Michael T McHale; Russell J Schilder; Anniina Färkkilä; Dipanjan Chowdhury; Jennifer Curtis; Roxanne S Quinn; Brittany Bowes; Alan D D'Andrea; Geoffrey I Shapiro; Ursula A Matulonis
Journal:  Lancet Oncol       Date:  2020-06-15       Impact factor: 41.316

4.  Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Authors:  Jeanne M Quinn; Molly M Greenwade; Marguerite L Palisoul; Gregory Opara; Katina Massad; Lei Guo; Peinan Zhao; Hollie Beck-Noia; Ian S Hagemann; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2018-11-26       Impact factor: 6.261

5.  Hypoxia-induced down-regulation of BRCA1 expression by E2Fs.

Authors:  Ranjit S Bindra; Shannon L Gibson; Alice Meng; Ulrica Westermark; Maria Jasin; Andrew J Pierce; Robert G Bristow; Marie K Classon; Peter M Glazer
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

6.  Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells.

Authors:  Ranjit S Bindra; Paul J Schaffer; Alice Meng; Jennifer Woo; Kårstein Måseide; Matt E Roth; Paul Lizardi; David W Hedley; Robert G Bristow; Peter M Glazer
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

7.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

8.  Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

Authors:  Eric Pujade-Lauraine; Keiichi Fujiwara; Jonathan A Ledermann; Amit M Oza; Rebecca Kristeleit; Isabelle-Laure Ray-Coquard; Gary E Richardson; Cristiana Sessa; Kan Yonemori; Susana Banerjee; Alexandra Leary; Anna V Tinker; Kyung Hae Jung; Radoslaw Madry; Sang-Yoon Park; Charles K Anderson; Fabian Zohren; Ross A Stewart; Caimiao Wei; Samuel S Dychter; Bradley J Monk
Journal:  Lancet Oncol       Date:  2021-06-15       Impact factor: 41.316

9.  Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.

Authors:  Panagiotis A Konstantinopoulos; Steven Waggoner; Gregory A Vidal; Monica Mita; John W Moroney; Robert Holloway; Linda Van Le; Jasgit C Sachdev; Eloise Chapman-Davis; Gerardo Colon-Otero; Richard T Penson; Ursula A Matulonis; Young Bae Kim; Kathleen N Moore; Elizabeth M Swisher; Anniina Färkkilä; Alan D'Andrea; Erica Stringer-Reasor; Jing Wang; Nathan Buerstatte; Sujata Arora; Julie R Graham; Dmitri Bobilev; Bruce J Dezube; Pamela Munster
Journal:  JAMA Oncol       Date:  2019-08-01       Impact factor: 31.777

10.  Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.

Authors:  Michal M Hoppe; Patrick Jaynes; Joanna D Wardyn; Sai Srinivas Upadhyayula; Tuan Zea Tan; Stefanus Lie; Diana G Z Lim; Brendan N K Pang; Sherlly Lim; Joe P S Yeong; Anthony Karnezis; Derek S Chiu; Samuel Leung; David G Huntsman; Anna S Sedukhina; Ko Sato; Monique D Topp; Clare L Scott; Hyungwon Choi; Naina R Patel; Robert Brown; Stan B Kaye; Jason J Pitt; David S P Tan; Anand D Jeyasekharan
Journal:  EMBO Mol Med       Date:  2021-03-11       Impact factor: 12.137
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.